The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study.
Modern treatment, a healthy diet, and physical activity routines lower the risk factors for metabolic syndrome; however, this condition is associated with all-cause and cardiovascular mortality worldwide. This investigation involved a randomized controlled trial, double-blind, parallel study. Fifty-...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0317202 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849315454637572096 |
|---|---|
| author | Wongsakorn Luangphiphat Pinidphon Prombutara Praewpannarai Jamjuree Chantanapa Chantarangkul Porntipha Vitheejongjaroen Chantaluck Muennarong Krittapat Fukfon Manasvin Onwan Malai Taweechotipatr |
| author_facet | Wongsakorn Luangphiphat Pinidphon Prombutara Praewpannarai Jamjuree Chantanapa Chantarangkul Porntipha Vitheejongjaroen Chantaluck Muennarong Krittapat Fukfon Manasvin Onwan Malai Taweechotipatr |
| author_sort | Wongsakorn Luangphiphat |
| collection | DOAJ |
| description | Modern treatment, a healthy diet, and physical activity routines lower the risk factors for metabolic syndrome; however, this condition is associated with all-cause and cardiovascular mortality worldwide. This investigation involved a randomized controlled trial, double-blind, parallel study. Fifty-eight participants with risk factors of metabolic syndrome according to the inclusion criteria were randomized into two groups and given probiotics (Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1) (n = 31) or a placebo (n = 27). The participants had a mean age of 42.29 ± 7.39 and 43.89 ± 7.54 years in the probiotics and placebo groups, respectively. Stool samples, anthropometric data, and blood chemistries were taken at baseline and at 12 weeks. The primary outcome was achieved by the probiotics group as their low-density lipoprotein-cholesterol level dramatically lowered compared to the placebo group (the difference was 39.97 ± 26.83 mg/dl, p-value <0.001). Moreover, significant reductions in body weight, body mass index, waist circumference, systolic blood pressure, and total cholesterol were observed in the volunteers treated with probiotics compared to the placebo. In the gut microbiome analysis, the results showed statistically significant differences in the beta diversity in the post-intervention probiotics group. Blautia, Roseburia, Collinsella, and Ruminococcus were among the gut microbiomes that were more prevalent in the post-intervention probiotics group. In addition, this group exhibited increases in the predicted functional changes in ATP-binding cassette (ABC) transporters, as well as ribonucleic acid transport, the biosynthesis of unsaturated fatty acids, glycerophospholipid metabolism, and pyruvate metabolism. In conclusion, this research demonstrated that the probiotics L. paracasei MSMC39-1 and B. animalis TA-1 have the efficacy to lower risk factors associated with metabolic syndrome. |
| format | Article |
| id | doaj-art-cfd3a2d2624542c28ac58755fcbd29c2 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-cfd3a2d2624542c28ac58755fcbd29c22025-08-20T03:52:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01201e031720210.1371/journal.pone.0317202The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study.Wongsakorn LuangphiphatPinidphon PrombutaraPraewpannarai JamjureeChantanapa ChantarangkulPorntipha VitheejongjaroenChantaluck MuennarongKrittapat FukfonManasvin OnwanMalai TaweechotipatrModern treatment, a healthy diet, and physical activity routines lower the risk factors for metabolic syndrome; however, this condition is associated with all-cause and cardiovascular mortality worldwide. This investigation involved a randomized controlled trial, double-blind, parallel study. Fifty-eight participants with risk factors of metabolic syndrome according to the inclusion criteria were randomized into two groups and given probiotics (Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1) (n = 31) or a placebo (n = 27). The participants had a mean age of 42.29 ± 7.39 and 43.89 ± 7.54 years in the probiotics and placebo groups, respectively. Stool samples, anthropometric data, and blood chemistries were taken at baseline and at 12 weeks. The primary outcome was achieved by the probiotics group as their low-density lipoprotein-cholesterol level dramatically lowered compared to the placebo group (the difference was 39.97 ± 26.83 mg/dl, p-value <0.001). Moreover, significant reductions in body weight, body mass index, waist circumference, systolic blood pressure, and total cholesterol were observed in the volunteers treated with probiotics compared to the placebo. In the gut microbiome analysis, the results showed statistically significant differences in the beta diversity in the post-intervention probiotics group. Blautia, Roseburia, Collinsella, and Ruminococcus were among the gut microbiomes that were more prevalent in the post-intervention probiotics group. In addition, this group exhibited increases in the predicted functional changes in ATP-binding cassette (ABC) transporters, as well as ribonucleic acid transport, the biosynthesis of unsaturated fatty acids, glycerophospholipid metabolism, and pyruvate metabolism. In conclusion, this research demonstrated that the probiotics L. paracasei MSMC39-1 and B. animalis TA-1 have the efficacy to lower risk factors associated with metabolic syndrome.https://doi.org/10.1371/journal.pone.0317202 |
| spellingShingle | Wongsakorn Luangphiphat Pinidphon Prombutara Praewpannarai Jamjuree Chantanapa Chantarangkul Porntipha Vitheejongjaroen Chantaluck Muennarong Krittapat Fukfon Manasvin Onwan Malai Taweechotipatr The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study. PLoS ONE |
| title | The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study. |
| title_full | The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study. |
| title_fullStr | The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study. |
| title_full_unstemmed | The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study. |
| title_short | The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study. |
| title_sort | efficacy of lacticaseibacillus paracasei msmc39 1 and bifidobacterium animalis ta 1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome a randomized double blinded placebo controlled study |
| url | https://doi.org/10.1371/journal.pone.0317202 |
| work_keys_str_mv | AT wongsakornluangphiphat theefficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT pinidphonprombutara theefficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT praewpannaraijamjuree theefficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT chantanapachantarangkul theefficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT porntiphavitheejongjaroen theefficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT chantaluckmuennarong theefficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT krittapatfukfon theefficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT manasvinonwan theefficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT malaitaweechotipatr theefficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT wongsakornluangphiphat efficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT pinidphonprombutara efficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT praewpannaraijamjuree efficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT chantanapachantarangkul efficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT porntiphavitheejongjaroen efficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT chantaluckmuennarong efficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT krittapatfukfon efficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT manasvinonwan efficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy AT malaitaweechotipatr efficacyoflacticaseibacillusparacaseimsmc391andbifidobacteriumanimalista1probioticsinmodulatinggutmicrobiotaandreducingtheriskofthecharacteristicsofmetabolicsyndromearandomizeddoubleblindedplacebocontrolledstudy |